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CASE REPORT
Signs of Psychosis Leading to a Diagnosis of Progressive 
Multifocal Leukoencephalopathy: A Case Report
Bryan L. Walker, MD,1 Christina Holt, MD, MSc1
1Department of Family Medicine, Maine Medical Center, Portland, ME
A 39-year-old male was found wandering the lobby of this hospital by security personnel. He appeared confused and was escorted to 
the emergency department. He was oriented only to 
self and unable to state a reason for presentation. 
His medical records revealed sparse, episodic care. 
In 2016, he was seen at an outside hospital that 
documented a history of human immunodeficiency 
virus (HIV) infection with last use of antiretroviral 
therapy (ART) one year prior.
In the emergency department, he was unable to 
follow instructions for a complete physical exam. 
Limited neurological exams were still performed 
and generally documented as “nonfocal,” 
suggesting no easily perceptible muscle weakness, 
speech abnormality, or gait disturbance was 
present. However, several physicians noted that he 
exhibited multiple signs of psychosis, including a 
disorganized thought process, abrupt interruptions 
in speech consistent with thought blocking (e.g., 
patient stated “I just need you to…” and then would 
stop talking), apparent responses to internal stimuli 
(e.g., during an interview, patient suddenly pointed 
into space and said, “really want something else”), 
and nonsensical answers to providers’ questions 
(e.g., when asked if he had friends or family, patient 
responded, “other things to go - supposed to be. I’m 
already tracing everything”).
Head computed tomography (CT) showed patchy 
areas of hypodensity within subcortical white 
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Introduction: Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating process of the central 
nervous system that occurs in patients who are severely immunocompromised. Patients with PML 
develop varying focal neurological deficits and mental status changes that have not been well-
described.  
Clinical findings: We present a patient who was found wandering the lobby of this hospital by security. He was oriented 
only to self and unable to state a reason for presentation. Medical records were limited and included 
a visit to an outside hospital that documented a past medical history of human immunodeficiency 
virus (HIV) infection. He exhibited multiple signs of psychosis, such as thought blocking and a 
disorganized thought process.
Diagnoses,
Interventions,
and Outcomes:
After thorough evaluation, he was diagnosed with HIV-associated PML based on a CD4 count of 68 
cells/µL, signal abnormalities in subcortical white matter on brain MRI, and positive cerebrospinal 
fluid polymerase chain reaction (PCR) for JC virus (JCV). Despite initiation of antiretroviral therapy 
(ART), the patient clinically declined and was ultimately transitioned to hospice care. 
Conclusions: While survival from PML has significantly improved with the advent of ART, the overall prognosis 
remains poor. This case report emphasizes that PML should be included in the differential diagnosis 
for immunocompromised patients with mental status changes, even if they do not present with overt 
focal neurological deficits. It also highlights the importance of continuous medical care for HIV to 
minimize the risk of patients developing such devastating complications.
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matter (Figure 1A, B). HIV-1 antibody was positive. 
CD4 count was 68 cells/µL (reference range 577–
1623). Brain magnetic resonance imaging (MRI) 
showed areas of signal abnormality in subcortical 
white matter concerning for progressive multifocal 
leukoencephalopathy (PML) (Figure 1C, D). 
Polymerase chain reaction studies of cerebrospinal 
fluid were positive for JC virus, confirming 
the diagnosis of PML. ART was initiated with 
emtricitabine-tenofovir alafenamide (200–25 mg 
daily) and dolutegravir (50 mg daily).
The patient’s clinical course was complicated by 
intermittent refusal of care, several attempts to elope 
from the unit, and marked behavioral dysregulation 
requiring antipsychotic therapy. Unfortunately, no 
personal contacts could be identified after extensive 
outreach attempts. Emergency guardianship was 
granted to the state. Despite treatment, his clinical 
condition declined with loss of mobility, dysphagia, 
and seizures. Given his progressive course and 
poor prognosis, care was transitioned to comfort 
measures and he was discharged with hospice 
services.
DISCUSSION
Progressive multifocal leukoencephalopathy is 
a demyelinating process of the central nervous 
system that was first described in 1958.1 It is 
caused by the JCV, which is estimated to lie 
dormant in 39–91% of the world’s population.2 
The virus is reactivated in the setting of severe 
immunocompromise due to either an underlying 
disorder (e.g., HIV) or immunomodulatory therapies 
(e.g., natalizumab, rituximab).3 The vast majority of 
patients with HIV infection who develop PML have 
CD4-positive T-cell counts < 200 per mm.3 Thus, the 
Centers for Disease Control and Prevention (CDC) 
classified PML as an acquired immunodeficiency 
syndrome (AIDS)–defining opportunistic illness 
(OI).4 In patients with at least one AIDS-defining 
OI, only 1.0% present with PML as the first OI to 
occur, making PML a rare initial complication of HIV 
infections.5
Patients with PML typically develop focal 
neurological deficits, depending on the specific 
brain regions affected by the demyelination. Thus, 
presenting symptoms can vary widely between 
patients and include hemiparesis, ataxia, aphasia, 
hemianopsia, and mental status changes.6 The 
precise characteristics of mental status changes 
are not well described in the literature. Most studies 
have typically grouped together patients exhibiting 
confusion, dementia, or obtundation, and then 
simply reported the total as a percentage of patients 
with altered mentation or cognitive dysfunction.6,7 
While such patients may have shared certain initial 
clinical features with the patient we present, the 
exact cognitive abnormalities they demonstrated 
remains unclear. Additionally, there are only a few 
case reports that highlight atypical presentations 
of PML, such as with HIV-associated dementia.8 
To our knowledge, this case report is the first to 
thoroughly describe a patient with HIV-associated 
PML presenting to medical care with signs of 
psychosis.
To date, there are no specific targeted treatments 
for PML. The main approach to treatment is 
restoring the patient’s immune system with 
effective ART to allow for normal host response to 
the JCV.9 Prior to the advent of effective ART in the 
mid-1990s, the one-year survival rate of patients 
with HIV-associated PML was just 10%.6 Now, 
initiation of effective ART significantly improves 
survival rates.10–13 In one study, the median survival 
time increased from 0.4 to 1.8 years in patients 
diagnosed with PML after 1997.13 The authors note 
that while survival has significantly improved, the 
overall prognosis for patients with PML remains 
poor, with a high mortality rate and high degree of 
neurological sequelae among survivors.
Unfortunately, this patient had previously received 
outpatient HIV treatment only briefly and was 
subsequently lost to follow-up. He was one of the 
hundreds of thousands of patients across the country 
who are not receiving ART through continuous HIV 
medical care. Recent surveillance data from the 
CDC shows that of the 794,145 teenage and adult 
patients with HIV infection in the United States, 
only 57.2% were retained in HIV care.14 In a large, 
population-based study in the United States, nearly 
half of all cases of the most common serious OI, 
Pneumocystis carinii pneumonia, occurred in 
persons not receiving medical care.15 Effective ART 
significantly protects against the development of 
all OIs, and since its introduction, the incidence of 
these diseases has declined precipitously in the 
US.15–19 Increased efforts are urgently needed to 
implement and develop effective interventions to 
help patients establish and remain in HIV care.20 
Without such ongoing care, patients will remain 
susceptible to devastating complications, as seen 
in this case report.
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Figure 1.  Neuroimaging
Panel A, B: Non-contrast axial CT head images showing patchy areas of hypodensity within the 
subcortical white matter of the bilateral temporal and anterolateral frontal lobes. 
Panel C, D: Axial T2-weighted FLAIR MR images demonstrating confluent signal abnormalities in the 
subcortical white matter corresponding to the lesions identified on the CT.
CT, computed tomography; MR, magnetic resonance; FLAIR, fluid-attenuated inversion recovery
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